Stories of Early Cancer Detection

Hear the experiences of several individuals whose lives were touched by multi-cancer early detection screening.

Up Next

How Rich Found his Cancer Early

How Rich Found his Cancer Early

Rich took a multi-cancer early detection test, offered by his Nationwide life insurance policy. To his surprise, the results led to a cancer diagnosis.

Up Next

Cindy’s Experience with Early Stage Lymphoma

Cindy’s Experience with Early Stage Lymphoma

Though Cindy had no symptoms, her husband, Carlos, urged her to take a multi-cancer early detection test. They were shocked when she received a “cancer signal detected” result.

Up Next

Detecting Pancreatic Cancer Early

Detecting Pancreatic Cancer Early

After being diagnosed with early stage pancreatic cancer, Roger’s doctor said he was the luckiest person he’d ever met.

Up Next

Mary’s Early Cancer Detection

Mary reading at kitchen table

Mary’s Early Cancer Detection

Mary’s physician gave her a clean bill of health at her annual physical. Then, a multi-cancer early detection test found a positive cancer signal in her blood.

Up Next

Stories of Early Cancer Detection

Our Mission

Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe and effective technologies that can transform cancer care.

Join Our Team
A Grail lab technician working
The Galleri® Test

The Galleri test is a first-of-its-kind multi-cancer early detection (MCED) test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.

Learn More
Multi-Cancer Early Detection

Multi-cancer early detection (MCED) blood tests analyze DNA that has been shed by all cells, including cancer cells, into the bloodstream, looking for abnormal methylation patterns on those cell-free DNA fragments that may indicate the presence of cancer.

Learn More
Methylation

GRAIL’s methylation technology preferentially targets the most informative regions of the genome and uses machine-learning algorithms to detect methylation patterns associated with cancer and when found, to predict the cancer signal origin.

Learn More

Who We Are

GRAIL is a healthcare company innovating to solve medicine’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it is more treatable and potentially curable.

Learn About Us
Grail lab technicians working

On this monthly podcast, Host Kim Thiboldeaux explores topics relating to multi-cancer early detection, such as its origin and evolution, the science behind it, and insight into how this technology has the potential to shift the cancer paradigm.